Article
Combined cranial and large vessel ultrasound and PET/CT provided excellent accuracy for the diagnosis of giant cell arteritis (GCA).
All News
Article
Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" documentopens in a new tab or window from the European Alliance of Associations for Rheumatology (EULAR).
Dr. John Cush
Tweet
Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform.
https://t.co/2hqKVhtzbv https://t.co/2dTvdU2A9t
Dr. John Cush
Tweet
Biosimilars Match Biologic Originators in RA
A JAMA review shows that biosimilars of adalimumab, infliximab, and etanercept were associated w/clinically equivalent treatment effects compared with their ref biologics for treatment of RA.
https://t.co/MqxqpzzpiJ https://t.co/Eh98wBUHlj
Dr. John Cush
Tweet
Time to Risk Stratify Methotrexate Lab Monitoring?
A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.
https://t.co/lpRhRYg7dd https://t.co/kU2gs3Oljg
Dr. John Cush
Tweet
Metanalysis of 62 RCTs, 16 LTEs of JAKi, placebo, TNFi, & MTX Rx pts shows that malignancy incidence rate =1.15-1.26/100 Pt-Yrs. Neoplasia risk w/ JAKi = PBO or MTX risk (IRR 0.71 & 0.77); but JAKi CA risk if compared to TNFi (IRR 1.50;1.16 to 1.94) https://t.co/uOgPFlJ2z1 https://t.co/Ynh6SMQdke
Dr. John Cush
Tweet
#RA pts at increased risk of gastroparesis (GP). From 2012–2014 National Inpatient Sample database; among 1.5 million RA, 1070 hospitalized for GP (OR 1.36; 1.24 to 1.49,P< 0.0001). GP risk incr by aging up to 65 yrs, DM, RA, income 26-75th percentiles https://t.co/2U4vSTtxen https://t.co/ub4z4ntcNk
Dr. John Cush
Tweet
TNR- Rheumatoid Arthritis - Decisive Therapeutics
Replay of this RA pod from RheumNow Live 2023, recorded on March 18, 2023
https://t.co/RyyKQFDrT5 https://t.co/ZHjJRzHJ0Q
Dr. John Cush
Tweet
RheumNow Eular 2023 Daily Recap Series - Day3
June 2, 2023 RheumNow faculty and reporters provide a daily recap of conference content coverage.
https://t.co/4aHy2uJOc6 https://t.co/zOBMX7sgXl
Dr. John Cush
Tweet
Update on CAR T-Cell Therapy in SLE & Autoimmune Diseases
Dr. Peter Nash ( @drpnash ) reporting from EULAR 2023 in Milan, Italy.
https://t.co/UNXLD5GVKi https://t.co/q8OAexChBN
Dr. John Cush
Tweet
Artificial Intelligence in Rheumatology: Now and the Future
Drs. Antoni Chan and Thomas Hugle discuss abstract POS0892 from EULAR 2023 in Milan, Italy.
https://t.co/rftHTKY6MX
@synovialjoints https://t.co/PtlKg4o18s
Dr. John Cush
Tweet
WATCH: JAKpot or JAKnot
Dr. Jack Cush, executive editor of RheumNow, reporting on abstract OP0219 from EULAR 2023 in Milan, Italy.
https://t.co/RSJX4hcMRU https://t.co/XYuOrSCxjf
Dr. John Cush
Tweet
EULAR 2023 recommendation for imaging in large vessel vasculitis
Diagnosis of large vessel vasculitis can be challenging, and imaging modalities help with not only the diagnosis but sometimes in assessing flares in the disease.
https://t.co/o8cpSOXNy4
@bella_mehta https://t.co/aCM3yzT32e
Dr. John Cush
Tweet
Report of 54 nonradiographic axial SpA pts w/ recurrent fever. Fever preceded SpA in all; age @ axSpA Dx 39.9 yrs, w/ Dx delay 9.3 yrs. Fevers 38-42°C, arthralgia 61%, myalgia 44%, arthritis 41%, GI 25%, Rash 22%. Best Rx to TNFi > IL1i, colchicine, DMARD https://t.co/muSYhZFXku https://t.co/1lUPCMyuCX
Dr. John Cush
Tweet
Karolinska SARA (secretory antibodies in RA) study of 132 RA pts found salivary IgA anti-RgpB Abs signif higher in RA than (p = 0.022), & were assoc w/ disease activity (p = 0.036), but not with periodontitis or serum IgG ACPA. https://t.co/4uul4b5Fhg https://t.co/R5WVCyjc3B
Dr. John Cush
Tweet
RheumNow Eular 2023 Daily Recap Series - Day1 & 2
RheumNow faculty and reporters provide a daily recap of conference content coverage.
https://t.co/GCDmZT5dyE https://t.co/tXV9qDmcEu
Dr. John Cush
Tweet
Should we be reassured of JAK safety with new data?
Dr. Janet Pope discusses abstracts OP0133 and OP0132 at EULAR 2023 in Milan, Italy.
https://t.co/Gf4puWXkLY https://t.co/kcnpfEpnTW
Dr. John Cush
Tweet
Still's Disease Abstracts at EULAR 2023
https://t.co/lb1QRcsa9G https://t.co/JIBszS7s7D
Dr. John Cush
Tweet
Watch: IRAEs, Targeted Therapies and Survival
Dr. Aurelie Najm discusses OP0270 presented at EULAR 2023 in Milan, Italy.
@AurelieRheumo
https://t.co/501Rc4SPY1 https://t.co/Ifw93ICqwW
Dr. John Cush
Tweet
Novel drug in development, LY3361237, is a BTLA (B & T lymphocyte attenuator) agonistic antibody to treat autoimmune Dz (eg SLE) - augments immune responses by activating checkpoint inhibitory receptors (CIRs). https://t.co/3iYq9UwHww https://t.co/RwrhqRO8cm https://t.co/tl8qVIXqjc
